Treakisym is an anticancer agent that exhibits both nitrogen mustard-derived alkylating activity and antimetabolic-like activity.
Treakisym is the subject of a licensing agreement concluded between Eisai and SymBio Pharmaceuticals, under which SymBio is responsible for developing and obtaining marketing approval for the drug in Japan, while Eisai will market it exclusively.
In the clinical studies Treakisym demonstrated efficacy, with a high response rate, and extended the duration of progression-free survival, Eisai said.